We are live on ! Find out more
UBX

Unity Biotechnology
UBX

Delisted

UBX was delisted on the 8th of July, 2025.

Back to rankings

40 hedge funds and large institutions have $6.87M invested in Unity Biotechnology in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,727% more call options, than puts

Call options by funds: $4.08M | Put options by funds: $70K

30% more capital invested

Capital invested by funds: $5.28M → $6.87M (+$1.6M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3.3% less ownership

Funds ownership: 22.05% → 18.75% (-3.3%)

13% less funds holding

Funds holding: 46 → 40 (-6)

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

Holders
40
Holders Change
-6
Holders Change %
-13.04%
% of All Funds
0.63%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
5
Increased
7
Reduced
11
Closed
11
Calls
$4.08M
Puts
$70K
Net Calls
+$4.01M
Net Calls Change
+$1.78M

Top Buyers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
+$114K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$103K
3
VF
Virtu Financial
New York
+$47.4K
4
PCIA
Prime Capital Investment Advisors
Kansas
+$30.2K
5
BlackRock
BlackRock
New York
+$19.4K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$761K
2
ECM
ExodusPoint Capital Management
New York
-$153K
3
AWA
Arete Wealth Advisors
Illinois
-$142K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$102K
5
Renaissance Technologies
Renaissance Technologies
New York
-$92.4K

UBX Hedge Fund Activity: Q2 2023 in Review

40 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q2 2023, worth a combined $6.87M — up 30% from $5.28M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of UBX and 5 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 7 added.

The largest buyer was Wells Fargo, adding an estimated $114K. The largest seller was Fidelity Investments, cutting an estimated $761K.

  • 40 institutional investors held Unity Biotechnology (UBX) as of Q2 2023, down from 46 in Q1 2023.
  • Funds reported $6.87M of Unity Biotechnology stock for Q2 2023, up 30% quarter-over-quarter.
  • 5 funds opened new Unity Biotechnology positions in Q2 2023 and 11 closed out, a net change of -6 holders.
  • The largest Unity Biotechnology buyer in Q2 2023 was Wells Fargo, an estimated $114K added.
  • The largest Unity Biotechnology seller in Q2 2023 was Fidelity Investments, an estimated $761K sold.

Based on aggregated 13F filings for Q2 2023.